We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Renal Cell Carcinoma

Journal Scan / Research · April 08, 2021

Pegilodecakin as Monotherapy or in Combination With Anti–PD-1 or TKI in Heavily Pretreated Patients With Advanced RCC

International Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

International Journal of Cancer
Pegilodecakin as Monotherapy or in Combination With Anti-PD-1 or Tyrosine Kinase Inhibitor in Heavily Pretreated Patients With Advanced Renal Cell Carcinoma (RCC): Final Results of Cohorts A, G, H, and I of IVY Phase I Study
Int. J. Cancer 2021 Mar 12;[EPub Ahead of Print], NM Tannir, KP Papadopoulos, DJ Wong, R Aljumaily, A Hung, M Afable, JS Kim, D Ferry, A Drakaki, J Bendell, A Naing

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading